ARQT Share Price Performance
US$29.49
18.72 (173.82%)
4.9% undervalued intrinsic discount
US$31.00
Fair Value
Price US$29.49
AnalystConsensusTarget US$31.00
Coward_Nutlick US$40.00
Fair ValueUS$31.00
Share Pricen/a
Arcutis Biotherapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 51 Fair Values set on narratives written by author
ARQT Community Narratives
AN
Fair Value US$31 n/aintrinsic discount
Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises
0users have liked this narrative
0users have commented on this narrative
26users have followed this narrative
CO
Fair Value US$40 26.3% undervalued intrinsic discount
Very Bullish
2users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
Very Bullish
It is almost impossible to obtain a drug label from the FDA for pediatric use - this topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.Read more
2users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
CO
US$40
26.3% undervalued intrinsic discount
Coward_Nutlick Fair Value
Revenue growth
35.69% p.a.
Profit Margin
21.21%
Future PE
29.38x
Share price in 2030
US$55.82
Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises
Key Takeaways Expansion of ZORYVE indications and partnerships targets underserved populations, supporting sustained revenue and margin improvement through diversification and operating leverage. Demand for innovative non-steroidal treatments and ongoing R&D investments enhance long-term growth, portfolio expansion, and market share amid favorable demographic trends.Read more
0users have liked this narrative
0users have commented on this narrative
26users have followed this narrative
AN
US$31
n/aintrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
31.56% p.a.
Profit Margin
35.91%
Future PE
19.6x
Share price in 2028
US$37.79
Recently Updated Narratives
CO
Very Bullish
Fair Value: US$40 26.3% undervalued intrinsic discount
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises
Fair Value: US$31 0% overvalued intrinsic discount
26 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Arcutis Biotherapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.36
- 89.96%
- -13.94%
- 68.6%
About ARQT
- Founded
- 2016
- Employees
- 342
- CEO
- WebsiteView website
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
